A Comprehensive Guide to Liposomal Irinotecan: Definition, Mechanism, and Advantages

Cancer is one of the most threatening medical problems in medicine, and conventional treatments are usually so toxic and ineffective that they are hard to treat. Of all the cancer drugs, irinotecan has been one of the more popular therapies for a wide variety of cancers, including metastatic pancreatic ductal adenocarcinoma (mPDAC). But standard irinotecan therapy has its limitations (including adverse effects and pharmacokinetics), so alternative formulations must be devised. Liposomal irinotecan (nal-IRI) is one of those developments, which uses a pegylated liposome formulation to deliver irinotecan as efficiently as possible with as few side effects as possible.

* Related Products & Services from BOC Sciences

What is Irinotecan?

Irinotecan is a chemotherapeutic drug, which acts as a topoisomerase I inhibitor. It acts by interrupting DNA replication in cancer cells. In particular, irinotecan attaches to topoisomerase I, an enzyme that makes short-term punctures in the DNA to permit replication. Once bound to this enzyme, irinotecan doesn't repair these breaks, which accumulates DNA damage and causes apoptosis of cells. Despite its success, however, there are some limitations with irinotecan that have kept its use in more widespread cancer treatment from spreading. The traditional formulation of irinotecan has inefficient pharmacokinetics — rapid excretion from the bloodstream, multiple doses required, and fluctuating concentrations. Moreover, due to the broad spectrum of the drug, it acts on both cancerous and normal tissues, toxicity is high, particularly in the gastrointestinal and hematological systems.

Structural chemical formula of irinotecan. (BOC Sciences Authorized)

Liposomal Irinotecan

Liposomal irinotecan is an advanced formulation of irinotecan encapsulated within liposomes—nanometer-sized vesicles made from lipid bilayers. This liposomal encapsulation alters the pharmacokinetics of the drug by enhancing its solubility, prolonging its circulation time in the bloodstream, and allowing for targeted drug delivery. Liposomal formulations are widely used in the pharmaceutical industry for their ability to improve the bioavailability and stability of poorly water-soluble drugs. Liposomal irinotecan works by encapsulating irinotecan within the lipid bilayers of the liposome, thereby reducing the toxicity associated with the free drug. The pegylation of the liposomes further enhances their pharmacokinetic properties by shielding them from immune system detection, prolonging the drug's half-life, and facilitating sustained release.

Liposomal Irinotecan Formulation

The structure of liposomal irinotecan (nal-IRI) is a sophisticated and well-engineered formulation designed to enhance the therapeutic efficacy of irinotecan while minimizing systemic toxicity. The liposomal delivery system allows for the encapsulation of irinotecan within liposomes, which are lipid-based vesicles that provide several advantages over conventional formulations. A liposome is a spherical vesicle composed of one or more bilayers of phospholipids, which are similar to the lipid bilayers of biological membranes. Liposomal irinotecan is encapsulated in nanometer-sized liposomes, typically ranging from 50 to 100 nm in diameter. The lipid bilayer serves as a protective barrier, preventing the premature release of irinotecan and stabilizing the drug in the bloodstream until it reaches the tumor site.

• Phospholipids : Phospholipids are the primary building blocks of the liposomal structure. Commonly used phospholipids in liposomal formulations include phosphatidylcholine (PC) and phosphatidylethanolamine (PE), which form the basic lipid bilayer. These phospholipids have hydrophilic heads and hydrophobic tails, enabling the formation of a stable bilayer structure that encapsulates hydrophobic drugs like irinotecan.
• Cholesterol: Cholesterol is incorporated into the liposome bilayer to enhance the stability and fluidity of the liposome. Cholesterol helps in membrane rigidity, making the liposomal structure more resistant to breakage and facilitating the encapsulation of drugs in the liposome's core. This stabilizing effect contributes to the prolonged circulation time of the liposomes in the bloodstream.
• Polyethylene Glycol (PEG): PEG is often attached to the surface of liposomes through PEGylation, a process that modifies the liposomal surface to improve the drug's pharmacokinetics. PEGylation reduces the likelihood of the liposome being recognized and cleared by the mononuclear phagocyte system (MPS), thereby increasing its half-life in circulation and allowing for sustained release of irinotecan. This modification enhances the bioavailability and targeting of the drug to tumor tissues.
• Irinotecan Encapsulation: Irinotecan, a hydrophobic chemotherapeutic agent, is encapsulated within the aqueous core of the liposome. The lipid bilayer protects the drug from degradation in the bloodstream and ensures controlled release at the tumor site. Irinotecan remains in a relatively inactive state within the liposome until it is delivered to the tumor.

* Related Products & Services from BOC Sciences

Advantages of Liposomal Irinotecan

The unique liposomal structure offers several advantages that enhance the effectiveness and safety of irinotecan therapy:

• Targeted Drug Delivery: Liposomes can accumulate in the tumor tissue through the enhanced permeability and retention (EPR) effect. Tumors often have leaky blood vessels, which allow liposomes to penetrate more easily and accumulate in the tumor, leading to increased local drug concentrations at the tumor site.
• Reduced Systemic Toxicity: The encapsulation of irinotecan in liposomes reduces the exposure of healthy tissues to the drug, thereby decreasing the systemic toxicity typically associated with conventional irinotecan, such as gastrointestinal disturbances and bone marrow suppression.
• Sustained Release: The controlled release of irinotecan from the liposomal structure allows for sustained drug delivery over a prolonged period, reducing the need for frequent dosing and improving therapeutic efficacy.
• Improved Pharmacokinetics: The use of PEGylation and the liposomal formulation improves the pharmacokinetics of irinotecan, allowing for longer circulation times and enhanced drug delivery to the target site.

The liposomal irinotecan formulation represents a significant improvement over traditional irinotecan therapies. By encapsulating irinotecan in liposomes, the drug's pharmacokinetic properties are optimized, leading to enhanced drug delivery, prolonged circulation time, and reduced toxicity. The unique liposomal structure protects irinotecan from premature degradation and ensures it is delivered more efficiently, ultimately improving the overall effectiveness of the treatment. Advancements in liposomal formulation technology continue to pave the way for more efficient and safer drug delivery systems.

How Does Liposomal Irinotecan Work?

The primary advantage of liposomal irinotecan lies in its drug delivery mechanism. Upon intravenous administration, the liposomes containing irinotecan circulate in the bloodstream and can preferentially accumulate in tumor tissues through a process known as the Enhanced Permeability and Retention (EPR) effect. The EPR effect occurs because the tumor vasculature is typically leaky, allowing liposomes to passively accumulate in tumor tissues, where they can slowly release the encapsulated drug.

• Once the liposomes are internalized by the tumor cells, the irinotecan is released in its active form. Liposomal irinotecan's liposomal formulation facilitates a controlled, sustained release of the drug over time, thereby maintaining therapeutic drug levels within the tumor while minimizing exposure to healthy tissues. This controlled release mitigates some of the common adverse effects of irinotecan, such as diarrhea, neutropenia, and other gastrointestinal toxicities, which are often a consequence of rapid, high-concentration drug exposure.
• Moreover, the pegylated liposomal form of irinotecan provides additional stability and bioavailability compared to its conventional formulation. The hydrophilic polyethylene glycol (PEG) coating prevents rapid recognition by the immune system, allowing the liposomes to remain in circulation for extended periods, which in turn leads to a longer duration of action and potentially better therapeutic outcomes.

What is Liposomal Irinotecan Used for?

Liposomal irinotecan, a formulation where irinotecan is encapsulated in liposomes, is widely studied in the field of drug delivery and cancer research. Researchers focus on its potential to enhance drug bioavailability and targetability, as well as its ability to reduce systemic toxicity compared to conventional formulations.

Tumor Targeting and Drug Delivery Research

Liposomal irinotecan offers an effective drug delivery system by exploiting the enhanced permeability and retention (EPR) effect. This property allows liposomes to accumulate in tumor tissues, which is a critical focus in cancer drug research. Studies are examining how liposomes can selectively target and deliver irinotecan more efficiently to cancer cells while minimizing exposure to healthy tissues.

Pharmacokinetics and Pharmacodynamics

In preclinical studies, liposomal irinotecan's pharmacokinetics are examined to assess how liposomal formulations impact drug circulation time, distribution, and bioavailability. The modification of liposomes (e.g., PEGylation) helps increase half-life and reduce clearance, enabling more efficient drug delivery to tumors. Research is focused on understanding these mechanisms to optimize therapeutic outcomes.

Exploring Liposomal Formulation for Other Anticancer Agents

Liposomal irinotecan is being researched in combination with other chemotherapeutic agents and targeted therapies. The goal is to enhance synergy and overcome chemoresistance in cancer treatment. Liposomes can protect unstable drugs and facilitate the simultaneous delivery of multiple therapeutic agents to improve overall treatment efficacy.

Addressing Drug Resistance

Studies focus on how liposomal irinotecan might overcome drug resistance mechanisms, such as efflux pumps or altered drug uptake. The liposomal formulation is being explored for its ability to increase intracellular drug concentration, thus offering a potential solution for chemoresistant tumors that are less responsive to conventional irinotecan therapies.

Liposomal Irinotecan FDA Approval – Onivyde

The U.S. FDA granted approval for Onivyde (nal-IRI) as part of a combination therapy for the treatment of metastatic pancreatic cancer, specifically for patients whose disease has progressed after prior treatment with gemcitabine-based regimens. Onivyde is used in conjunction with 5-FU and LV, and it is the first agent to receive specific approval for this indication.

The approval was based on the results of the pivotal NAPOLI-1 trial, a Phase III study that demonstrated a significant overall survival benefit for patients treated with liposomal irinotecan compared to 5-FU/LV alone. In addition to improving survival, nal-IRI + 5-FU/LV exhibited a manageable safety profile, which was essential for its acceptance in clinical practice. Most common grade 3-4 adverse events associated with the treatment were neutropenia and diarrhea, both of which can be mitigated with dose adjustments as necessary.

Onivyde's FDA approval marks a significant milestone in the treatment of pancreatic cancer, where effective second-line therapies were previously lacking. The liposomal formulation not only provides a more effective delivery of irinotecan but also offers a reduced toxicity profile, which is crucial in the management of patients with advanced cancer who often have compromised health status. The approval of liposomal irinotecan highlights the ongoing efforts to improve the efficacy and safety of chemotherapeutic agents, particularly for diseases such as mPDAC, where treatment options have historically been limited.